Mereo BioPharma (MREO) Income towards Parent Company (2023 - 2025)
Historic Income towards Parent Company for Mereo BioPharma (MREO) over the last 3 years, with Q3 2025 value amounting to -$7.0 million.
- Mereo BioPharma's Income towards Parent Company rose 5317.65% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 825.98%. This contributed to the annual value of -$43.3 million for FY2024, which is 4678.95% down from last year.
- Latest data reveals that Mereo BioPharma reported Income towards Parent Company of -$7.0 million as of Q3 2025, which was up 5317.65% from -$14.6 million recorded in Q2 2025.
- In the past 5 years, Mereo BioPharma's Income towards Parent Company registered a high of -$1.8 million during Q2 2023, and its lowest value of -$15.0 million during Q3 2024.
- For the 3-year period, Mereo BioPharma's Income towards Parent Company averaged around -$9.7 million, with its median value being -$9.1 million (2023).
- In the last 5 years, Mereo BioPharma's Income towards Parent Company plummeted by 59988.58% in 2024 and then skyrocketed by 5317.65% in 2025.
- Mereo BioPharma's Income towards Parent Company (Quarter) stood at -$9.1 million in 2023, then increased by 22.65% to -$7.0 million in 2024, then grew by 0.31% to -$7.0 million in 2025.
- Its last three reported values are -$7.0 million in Q3 2025, -$14.6 million for Q2 2025, and -$12.9 million during Q1 2025.